Electrocardiographic abnormalities in methamphetamine abusers

Addiction

Volumn 102, Issue SUPPL. 1, 2007, Pages 70-75

  Haning, William ^a   Goebert, Deborah ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Cardiotoxicity; Drug abuse; Electrocardiogram; Heart disease; Methamphetamine; QT interval

Indexed keywords

METHAMPHETAMINE; ONDANSETRON; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ABUSE PATTERN; DRUG DEPENDENCE TREATMENT; DRUG DOSE COMPARISON; ECG ABNORMALITY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SUBSTANCE ABUSE; TORSADE DES POINTES; UNITED STATES; VARIANCE;

ADOLESCENT; ADULT; AGED; AMPHETAMINE-RELATED DISORDERS; ARRHYTHMIA; CENTRAL NERVOUS SYSTEM STIMULANTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED;

EID: 33847306408     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2006.01776.x     Document Type: Article

References (46)

1. Hamakawa E. G., Hanabusa C., Aduja M. W. Final Report of the Joint House-Senate Task Force on Ice and Drug Abatement. Hawaii: State of Hawaii Legislative Reference Bureau; 2004.
2. Fernandez-Sola J., Estruch R., Grau J. M., Pare J. C., Rubin E., Urbano-Marquez A. The relation of alcoholic myopathy to cardiomyopathy. Ann Intern Med 1994; 120: 529-36.
3. Urbano-Marquez A., Estruch R., Navarro-Lopez F., Grau J. M., Mont L., Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989; 320: 409-15.
4. Inoue H., Nakatome M., Terada M., Mizuno M., Ono R., Iino M. et al. Maternal methamphetamine administration during pregnancy influences on fetal rat heart development. Life Sci 2004; 74: 1529-40.
5. Kaiho M., Ishiyama I. Morphological study of acute myocardial lesions experimentally induced by methamphetamine. Nippon Hoigaku Zasshi 1989; 43: 460-8.
6. Maeno Y., Iwasa M., Inoue H., Koyama H., Matoba R. Methamphetamine induces an increase in cell size and reorganization of myofibrils in cultured adult rat cardiomyocytes. Int J Legal Med 2000; 113: 201-7.
7. Yu Q., Montes S., Larson D. F., Watson R. R. Effects of chronic methamphetamine exposure on heart function in uninfected and retrovirus-infected mice. Life Sci 2002; 71: 953-65.
8. Hong R., Matsuyama E., Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991; 265: 1152-4.
9. Jacobs L. J. Reversible dilated cardiomyopathy induced by methamphetamine. Clin Cardiol 1989; 12: 725-7.
10. Nestor T., Tamamoto W., Kam T., Schultz T. Crystal methamphetamine- induced acute pulmonary edema. Hawaii Med J 1989; 48: 457-60.
11. Berankova K., Habrdova V., Balikova M., Strejc P. Methamphetamine in hair and interpretation of forensic findings in a fatal case. Forensic Sci Int 2005; 153: 93-7.
12. Turnipseed S. D., Richards J. R., Kirk J. D., Diercks D. B., Amsterdam E. A. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med 2003; 24: 369-73.
13. Karch S. B., Stephens B. G., Ho C. H. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci 1999; 44: 359-68.
14. Substance Abuse and Mental Health Services Administration. Tips for Teens: the Truth About Methamphetamine. Available at: http://ncadi.samhsa. gov/govpubs/PHD861/ (last accessed 27 January 2007).
15. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 2005; 5: 79-86.
16. Perez J. A., Arsura E. L., Strategos S. Methamphetamine-related stroke: four cases. J Emerg Med 1999; 17: 469-71.
17. White S. R. Amphetamine toxicity. Semin Respir Crit Care Med 2002; 23: 27-36.
18. YuQ., Larson D. F., Watson R. R. Heart disease, methamphetamine and AIDS. Life Sci 2003; 73: 129-40.
19. Newton T. F., Roache J. D., De La Garza R., Fong T., Wallace C. L., Li S. H. et al. Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology 2005; 182: 426-35.
20. Pavese N., Rimoldi O., Gerhard A., Brooks D. J., Piccini P. Cardiovascular effects of methamphetamine in Parkinson's disease patients. Mov Disord 2004; 19: 298-330.
21. Albertson T. E., Derlet R. W., Van Hoozen B. E. Methamphetamine and the expanding complications of amphetamines. West J Med 1999; 170: 214-9.
22. Gotway M. B., Marder S. R., Hanks D. K., Leung J. W. T., Dawn S. K., Gean A. D. et al. Thoracic complications of illicit drug use: an organ system approach. Radiographics 2002; 22: s119-35.
23. Mendelson J., Jones R. T., Upton R., Jacob P. Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther 1995; 57: 559-68.
24. Varner K. J., Hein N. D., Ogden B. A., Arsenault J. R., Carter K. M., Soine W. H. Chlorephedrine: contaminant of methamphetamine synthesis with cardiovascular activity. Drug Alcohol Depend 2001; 64: 299-307.
25. Johnson B. A., Wells L. T., Roache J. D., Wallace C., Ait-Daoud N., Wang Y. Isradipine decreases the hemodynamic response of cocaine and methamphetamine. Am J Hypertens 2005; 18: 813-22.
26. Schindler C. W., Gilman J. P., Graczyk Z., Wang G., Gee W. L. Reduced cardiovascular effects of methamphetamine following treatment with selegiline. Drug Alcohol Depend 2003; 72: 133-9.
27. Newton T. F., De La Garza R., Kalechstein A. D., Nestor L. Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharm Biochem Behav 2005; 82: 90-7.
28. Varner K. J., Ogden B. A., Delcarpio J., Meleg-Smith S. Cardiovascular responses elicited by the 'binge' administration of methamphetamine. J Pharm Exp Ther 2002; 301: 152-9.
29. Hicks A. R., Ogden B. A., Varner K. J. Cardiovascular responses elicited during binge administration of cocaine. Physiol Behav 2003; 80: 115-22.
30. Sheridan R. D., Turner S. R., Cooper G. J., Tattersall J. E. H. Effects of seven drugs of abuse on action potential repolarization in sheep cardiac Purkinje fibres. Eur J Pharmacol 2005; 511: 99-107.
31. Islam M. N., Kuroki H., Hongcheng B., Ogura Y., Kawaguchi N., Onishi S. et al. Cardiac lesions and their reversibility after long term administration of methamphetamine. Forensic Sci Int 1995; 75: 29-43.
32. Nakatome M., Matoba R., Ogura Y., Tun Z., Iwasa M., Maeno Y. et al. Detection of cardiomyocyte apoptosis in forensic autopsy cases. Int J Legal Med 2002; 116: 17-21.
33. Cubeddu L. X. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003; 10: 452-7.
34. Cruciani R. A., Sekine R., Homel P., Lussier D., Yap Y., Suzuki Y. et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 2005; 29: 385-91.
35. Benoit S. R., Mendelsohn A. B., Nourjah P., Staff J. A., Graham D. J. Risk factors for prolonged QTc among US adults: Third National Health Nutrition Study. Eur J Cardiovasc Prev Rehab 2005; 12: 363-8.
36. Krantz M. J., Rowan S. B., Mehler P. S. Cocaine-related torsade de pointes in a methadone maintenance patient. J Addict Dis 2005; 24: 53-60.
37. Chakko S., Sepulveda S., Kessler K. M., Sotomayor M. C., Mash D. C., Prineas R. J. et al. Frequency and type of electrocardiographic abnormalities in cocaine abusers (electrocardiogram in cocaine abuse). Am J Cardiol 1994; 74: 710-3.
38. Alonso J. L., Martinez P., Vallverdu M., Cygankiewicz I., Pitzalis M. V., Bayes Genis A. et al. Dynamics of ventricular repolarization in patients with dilated cardiomyopathy versus health subjects. Ann Noninvasive Electrocardiol 2005; 10: 121-8.
39. Corovic N., Durakovic Z., Misigoj-Durakovic M. Dispersion of the corrected QT and JT interval in the eelctrocardiogram of alcoholic patients. Alcohol Clin Exp Res 2006; 30: 150-4.
40. Diem B. H., Stellbrink C., Michel M., Schauerte P., Hanrath P. Temporary disturbances of the QT interval precede the onset of ventricular tachyarrhythmias in patients with structural heart diseases. Pacing Clin Electrophysiol 2002; 25: 1413-8.
41. Elming H., Brendorp B., Kober L., Sahebzadah N., Torp-Petersen C. QTc interval in the assessment of cardiac risk. Cardiol Electrophysiol Rev 2002; 6: 289-94.
42. Kuboki K., Ohkawa S., Chida K., Watanabe C., Ueda K., Sugiura M. Torsades de pointes in a case of hypertrophic cardiomyopathy with special reference to the pathologic findings of the heart including the conduction system. Jpn Heart J 1999; 40: 233-8.
43. Ryerson L. M., Giuffre R. M. QT intervals in metabolic dilated cardiomyopathy. Can J Cardiol 2006; 22: 217-20.
44. Savielieva I., Yap Y. G., Yi G., Guo X. H., Hnatkova K., Camm A. J. et al. Relation of ventricular repolarization to cardiac cycle length in normal subjects, hypertrophic cardiomyopathy, and patients with myocardial infarction. Clin Cardiol 1999; 22: 649-54.
45. Hamad A., Khan M. ST-segment elevation in patients with cocaine abuse and chest pain. is there a pattern? [Comment on Chakko et al. 1994.] Am J Cardiol 2000; 86: 1054.
46. Chang L., Haning W. Insights from recent positron emission tomographic studies of drug abuse and dependence. Curr Opin Psychiatry 2006; 19: 246-52.